MalarVx Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $1.05M
Latest Deal Amount
  • Investors
  • 1

MalarVx General Information


Operator of a bio-pharmaceutical company. The company is focused on the development of in vitro culture systems for the malaria parasite which will lead to the development of an effective whole-parasite vaccine.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Other Healthcare Services
Other Industries
Primary Office
  • 307 Westlake Avenue North
  • Suite 200
  • Seattle, WA 98109
  • United States
+1 (206) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MalarVx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC 21-Jun-2017 $1.05M 00.00 Completed Startup
1. Angel (individual) 23-Nov-2015 00000 00000 Completed Startup
To view MalarVx’s complete valuation and funding history, request access »

MalarVx Executive Team (2)

Name Title Board Seat Contact Info
James Davie Co-Founder, President & Chief Executive Officer
Paul Harris Ph.D Co-Founder & Vice President, Product Development
To view MalarVx’s complete executive team members history, request access »

MalarVx Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Keiretsu Forum Venture Capital Minority 000 0000 000000 0
To view MalarVx’s complete investors history, request access »